Expression of the fibronectin receptor VLA‐5 is regulated during human B cell differentiation and activation

• Published in: Clinical and experimental immunology Vol. 84; no. 2; pp. 336 - 346
• Main Authors: BALLARD, L. L., BROWN, E. J., HOLERS, V. M.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.05.1991; Blackwell
• Subjects: B cell activation; B cell ontogeny; B cells; B-Lymphocytes - metabolism; Biological and medical sciences; Blotting, Northern; Cell Differentiation - physiology; Cloning, Molecular; Fibronectins - metabolism; Flow Cytometry; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Gene Expression Regulation; Humans; Immunobiology; intcgrins; Lymphocyte Activation - physiology; Lymphoid cells: ontogeny, maturation, markers, receptors, circulation and recirculation; Palatine Tonsil - immunology; Receptors, Very Late Antigen - biosynthesis; RNA - analysis; VLAs; Human; Northern blotting; Flow cytometry; Immunoprecipitation reaction; Messenger RNA; Development; Activation; B-Lymphocyte; Cell differentiation; Fibronectin; Biological receptor
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1111/j.1365-2249.1991.tb08170.x

SUMMARY We examined the expression of VLA‐5, a libronectin receptor, during human B cell development and activation. VLA‐5 is a member of the integrin supergene family; VLAs arc heterodimers of at least six unique a chains sharing a common (i chain; most arc involved in cell attachment to extracellular matrix (ECM). A hypothesis of haematopoietic development is lhat maturing cells leave the bone marrow because of the loss of VLA‐5 during differentiation. However, mature B ceils are not primarily circulating cells, and the role of ECM receptors in homing to peripheral lymphoid tissue and inflammatory sites is unknown. To examine the expression of VLA‐5 during B cell development, cell lines blocked at specific stages of differentiation were evaluated for their synthesis and surface expression of VLA‐5 using VLA‐5‐specific antibody and cDNA probes. VLA‐5 mRNA and surface expression were found in the pre‐B cell lines, REH and Nall 1, but not in more differentiated Raji cells or in several EBV‐transformed peripheral B cell lines. Circulating peripheral B lymphocytes and resting tonsillar and splenic B lymphocytes expressed no VLA‐5 by FACS analysis. Interestingly, mRNA and surface expression of VLA‐5 were found in SKW. a highly differentiated, IgM‐secreting line. In addition, low levels of staining for VLA‐5 expression could be demonstrated when tonsillar or peripheral blood B lymphocytes were stimulated by Staphylococcus aureus Cowan (SAC). All cell lines expressed VLA‐3 and VLA‐4. two other receptors reported to mediate fibronectin binding in some cell types. Thus, our studies provided no evidence for developmental or inflammatory regulation of these receptors. Binding studies, however, demonstrated that adherence of both pre‐B REH cells and SKW cells to fibronectin was almost completely inhibited by a monoclonal antibody to VLA‐5o. In addition, Raji cells, which lack VLA‐5 but express VLA‐3 and VLA‐4. showed very low level binding to Hbronectin. This demonstrates that for some B lymphocytes VLA‐5, rather than other possible fibronectin receptors, primarily mediates attachment to fibronectin. These data also suggest that human VLA‐5 expression is regulated during B cell development, with expression at a very early stage and then again after activation. This pattern of loss and reacquisition of an ECM receptor may be relevant to normal B cell maturation and to function during immunologic injury.